Ligand Pharmaceuticals (NASDAQ:LGND) Posts Quarterly Earnings Results, Beats Estimates By $0.40 EPS

Ligand Pharmaceuticals (NASDAQ:LGND) released its earnings results on Thursday. The biotechnology company reported $2.37 EPS for the quarter, beating the consensus estimate of $1.97 by $0.40, FiscalAI reports. The company had revenue of $63.69 million for the quarter, compared to analyst estimates of $61.30 million. Ligand Pharmaceuticals had a net margin of 67.88% and a return on equity of 20.06%. The firm’s quarterly revenue was up 33.8% compared to the same quarter last year. During the same quarter last year, the firm earned $1.60 EPS. Ligand Pharmaceuticals updated its FY 2026 guidance to 9.000-9.500 EPS.

Here are the key takeaways from Ligand Pharmaceuticals’ conference call:

• Second-quarter results exceeded growth expectations, with total revenue up 34% year over year to $64 million, royalty revenue up 32% to $48 million, and adjusted diluted EPS up 48% to $2.37.
• The recently closed XOMA Royalty acquisition adds more than 120 assets, including seven commercial programs and approximately 14 late-stage clinical programs, and is expected to contribute about $0.50 of adjusted EPS in the second half of 2026 and $1.50 in 2027.
• Ligand raised the low end of 2026 adjusted EPS guidance to $9.00 while maintaining the $9.50 upper end, reaffirmed royalty revenue guidance of $225 million-$250 million, and retains approximately $700 million of deployable capital plus expected operating cash flow exceeding $200 million in 2026.
• Management highlighted a catalyst-rich 18-month period, including up to seven pivotal readouts and potential approvals or label expansions for products such as QTORIN rapamycin, OJEMDA, volixibat, and VABYSMO, while acknowledging the inherent binary risk of clinical development.
• Mirum’s volixibat program in primary sclerosing cholangitis faces a timeline delay after the FDA recommended a Phase III trial; Ligand said the company is pursuing further discussions and now targets a potential submission in the first half of 2027.

Ligand Pharmaceuticals Trading Down 2.3%

Shares of NASDAQ:LGND traded down $6.99 during midday trading on Friday, hitting $293.15. 313,611 shares of the stock traded hands, compared to its average volume of 300,344. The stock has a market capitalization of $5.87 billion, a PE ratio of 31.35, a P/E/G ratio of 2.71 and a beta of 1.13. The business’s 50 day moving average is $285.97 and its two-hundred day moving average is $235.30. The company has a quick ratio of 20.95, a current ratio of 34.52 and a debt-to-equity ratio of 1.16. Ligand Pharmaceuticals has a one year low of $137.14 and a one year high of $326.63.

Trending Headlines about Ligand Pharmaceuticals

Here are the key news stories impacting Ligand Pharmaceuticals this week:

• Positive Sentiment: Ligand reported second-quarter adjusted EPS of $2.37, beating analysts’ $1.95 consensus estimate, while revenue of $63.69 million exceeded expectations of $60.87 million. Revenue increased 33.8% year over year, and EPS rose from $1.60 in the prior-year quarter. Ligand Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company raised its fiscal 2026 adjusted EPS outlook to $9.00-$9.50, above the $8.13 analyst consensus. The outlook implies continued earnings growth and supports the investment case for Ligand’s royalty-focused business model. Ligand Pharmaceuticals Q2 Adjusted Earnings, Revenue Rise; 2026 Adjusted EPS Outlook Lifted, Revenue Outlook Reaffirmed
• Positive Sentiment: Royal Bank of Canada raised its price target from $340 to $345 and maintained an “outperform” rating. HC Wainwright also lifted its target from $289 to $358 and assigned a “buy” rating, signaling that analysts see further upside. Analyst Price Target Updates
• Neutral Sentiment: Ligand reaffirmed fiscal 2026 revenue guidance of $270 million-$310 million. Although the midpoint is below the $287.5 million consensus estimate, the range remains consistent with the company’s previous outlook and may reflect the timing of royalty and licensing revenue. Ligand Pharmaceuticals 2026 Q2 Results Presentation
• Negative Sentiment: The stock’s decline following the earnings beat suggests investors may have been looking for a larger revenue outlook increase or may be locking in gains after the shares’ strong run. The mixed revenue guidance could be limiting the immediate reaction to the otherwise favorable results. Biopharma Royalty Powerhouse Dips Despite Beat-and-Raise Quarter

Insider Buying and Selling

In other Ligand Pharmaceuticals news, insider Andrew Reardon sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $288.99, for a total transaction of $1,444,950.00. Following the completion of the transaction, the insider owned 41,514 shares of the company’s stock, valued at $11,997,130.86. This represents a 10.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stephen L. Sabba sold 2,145 shares of the stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $254.00, for a total value of $544,830.00. Following the completion of the sale, the director owned 33,629 shares of the company’s stock, valued at approximately $8,541,766. This trade represents a 6.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 35,231 shares of company stock valued at $9,199,401 over the last ninety days. Corporate insiders own 5.60% of the company’s stock.

Hedge Funds Weigh In On Ligand Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. CIBC Private Wealth Group LLC boosted its stake in shares of Ligand Pharmaceuticals by 86.3% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 149 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 69 shares in the last quarter. Kestra Advisory Services LLC bought a new stake in shares of Ligand Pharmaceuticals in the 4th quarter worth approximately $31,000. JPL Wealth Management LLC bought a new position in shares of Ligand Pharmaceuticals during the third quarter valued at $52,000. Persistent Asset Partners Ltd purchased a new position in Ligand Pharmaceuticals in the fourth quarter worth about $150,000. Finally, State of Wyoming purchased a new position in Ligand Pharmaceuticals in the fourth quarter worth about $169,000. Institutional investors own 91.28% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on LGND shares. HC Wainwright upped their price target on shares of Ligand Pharmaceuticals from $289.00 to $358.00 and gave the company a “buy” rating in a research report on Thursday. Stifel Nicolaus boosted their target price on Ligand Pharmaceuticals from $255.00 to $332.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. Citigroup initiated coverage on Ligand Pharmaceuticals in a report on Tuesday, July 21st. They set a “buy” rating and a $387.00 target price for the company. Royal Bank Of Canada raised their price target on Ligand Pharmaceuticals from $340.00 to $345.00 and gave the stock an “outperform” rating in a research report on Friday. Finally, Bank of America lifted their price target on Ligand Pharmaceuticals from $266.00 to $388.00 and gave the stock a “buy” rating in a research note on Thursday, July 9th. Seven research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $336.57.

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals, Inc is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas.

The company’s product offerings center around several core platforms.